Study for development of new treatment for antibody mediated rejection in organ transplantation

Study for development of new treatment for antibody mediated rejection in organ transplantation - Development of new treatment for antibody mediated rejection

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030525

Enrollment

Registered

2018-01-09

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

organ failure

Interventions

Administration with rituximab 375 mg/m2 once or twice

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with preoperative sensitization or with AMR Patients treated in registered institutions Patients eating or after organ transplantation (liver, heart, lung, pancreas, islet cells, small bowel) Patients who wish to participate this study for him/herself or whose gardens or representatives.

Exclusion criteria

Exclusion criteria: Patients with active infections, or malignancy, or patients whom the responsible person decided to be not appropriate.

Design outcomes

Primary

Measure	Time frame
Incidence of diminishment of HLA antibody in desensitization changes of clinico-pathological findings in treatment	—

Secondary

Measure	Time frame
Change of HLA antibody titers incidence of AMR incidence of ACR patient and graft survival organ functions adverse effects	—

Countries

Japan

Contacts

Public ContactHiroto Egawa

Tokyo Women's Medical University Department of Surgery

egawa.hiroto@twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026